CY1106436T1 - Φαινυλοφαινανθριδινες με δραση αναστολης pde - ιv - Google Patents

Φαινυλοφαινανθριδινες με δραση αναστολης pde - ιv

Info

Publication number
CY1106436T1
CY1106436T1 CY20061100209T CY061100209T CY1106436T1 CY 1106436 T1 CY1106436 T1 CY 1106436T1 CY 20061100209 T CY20061100209 T CY 20061100209T CY 061100209 T CY061100209 T CY 061100209T CY 1106436 T1 CY1106436 T1 CY 1106436T1
Authority
CY
Cyprus
Prior art keywords
phenylophenanthridines
inhibiting action
pde inhibiting
pde
action
Prior art date
Application number
CY20061100209T
Other languages
Greek (el)
English (en)
Inventor
Dieter Flockerzi
Hermann - AMSCHLER deceased
Gerhard Grundler
Armin Hatzelmann
Daniela Bundschuh
Rolf Beume
Hildegard Boss
Hans-Peter Kley
Beate Gutterer
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of CY1106436T1 publication Critical patent/CY1106436T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
CY20061100209T 1999-01-15 2006-02-14 Φαινυλοφαινανθριδινες με δραση αναστολης pde - ιv CY1106436T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99100694 1999-01-15
PCT/EP2000/000172 WO2000042020A1 (en) 1999-01-15 2000-01-12 Phenylphenanthridines with pde-iv inhibiting activity
EP00901534A EP1147089B1 (en) 1999-01-15 2000-01-12 Phenylphenanthridines with pde-iv inhibiting activity

Publications (1)

Publication Number Publication Date
CY1106436T1 true CY1106436T1 (el) 2011-10-12

Family

ID=8237351

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100209T CY1106436T1 (el) 1999-01-15 2006-02-14 Φαινυλοφαινανθριδινες με δραση αναστολης pde - ιv

Country Status (32)

Country Link
US (1) US6476025B1 (enExample)
EP (2) EP1147089B1 (enExample)
JP (1) JP4653314B2 (enExample)
KR (1) KR100720906B1 (enExample)
CN (1) CN1152864C (enExample)
AT (1) ATE312081T1 (enExample)
AU (1) AU774868B2 (enExample)
BG (1) BG65126B1 (enExample)
BR (1) BR0007527B1 (enExample)
CA (1) CA2359440C (enExample)
CY (1) CY1106436T1 (enExample)
CZ (1) CZ300366B6 (enExample)
DE (1) DE60024581T2 (enExample)
DK (1) DK1147089T3 (enExample)
EA (1) EA003780B1 (enExample)
EE (1) EE05105B1 (enExample)
ES (1) ES2254132T3 (enExample)
HK (1) HK1040997B (enExample)
HR (1) HRP20010578A2 (enExample)
HU (1) HU227624B1 (enExample)
ID (1) ID29070A (enExample)
IL (2) IL144026A0 (enExample)
NO (1) NO320182B1 (enExample)
NZ (1) NZ512872A (enExample)
PL (1) PL205670B1 (enExample)
RS (1) RS50297B (enExample)
SI (1) SI1147089T1 (enExample)
SK (1) SK286946B6 (enExample)
TR (2) TR200101938T2 (enExample)
UA (1) UA69436C2 (enExample)
WO (1) WO2000042020A1 (enExample)
ZA (1) ZA200104864B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006238A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
WO2004018431A2 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
WO2004019944A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
ES2281658T3 (es) 2002-08-29 2007-10-01 Nycomed Gmbh 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4.
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
JP2007500685A (ja) * 2003-07-31 2007-01-18 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規の６−フェニルフェナントリジン
CA2533636A1 (en) * 2003-07-31 2005-02-10 Altana Pharma Ag Novel 6-phenylphenanthridines
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
EP1720835B1 (en) * 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
HRP20130828T1 (en) 2004-03-03 2013-09-30 Takeda Gmbh Novel hydroxy-6-heroarylphenanthridines and their use as pde4 inhibitors
CA2558375A1 (en) * 2004-03-09 2005-09-15 Altana Pharma Ag Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
EP1725534A1 (en) * 2004-03-10 2006-11-29 Altana Pharma AG Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
AU2005219581A1 (en) * 2004-03-10 2005-09-15 Nycomed Gmbh Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
JP2007527900A (ja) * 2004-03-10 2007-10-04 アルタナ　ファルマ　アクチエンゲゼルシャフト チオ含有の新規のヒドロキシ−６−フェニルフェナントリジン及びｐｄｅ４インヒビターとしてのそれらの使用
EP1791847A2 (en) 2004-09-08 2007-06-06 Altana Pharma AG Novel 3-thia-10-aza-phenanthrene derivatives
US7411093B2 (en) * 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
NZ560268A (en) 2005-03-02 2010-12-24 Nycomed Gmbh Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
CN102600144A (zh) 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
WO2006095009A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
JP5362729B2 (ja) 2007-10-04 2013-12-11 エフ．ホフマン−ラ ロシュ アーゲー シクロプロピルアリールアミド誘導体及びその使用
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
BR112020018601A2 (pt) 2018-03-14 2020-12-29 Janssen Sciences Ireland Unlimited Company Regime de dosagem de modulador de montagem de capsídeo
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
TW202108576A (zh) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) * 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
EA001205B1 (ru) * 1996-01-31 2000-12-25 Бык Гульден Ломберг Хемише Фабрик Гмбх Новые фенантридины
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
WO1997035854A1 (de) * 1996-03-26 1997-10-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue in 6-position substituierte phenanthridine
ATE234300T1 (de) 1996-11-11 2003-03-15 Altana Pharma Ag Benzonaphthyridine als bronchialtherapeutika
WO1998040382A1 (en) 1997-03-07 1998-09-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tetrazoles
DK0988302T3 (da) 1997-06-03 2003-06-02 Altana Pharma Ag Benzonaphthyridiner
WO1999005113A1 (en) * 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted 6-phenylphenanthridines
CA2297923A1 (en) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tetrazole-substituted 6-phenyl-pheanathridines as pde inhibitors
ATE294793T1 (de) * 1999-01-15 2005-05-15 Altana Pharma Ag Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
ATE315029T1 (de) * 1999-01-15 2006-02-15 Altana Pharma Ag 6-arylphenanthridine mit pde-iv hemmender wirkung
SI1147087T1 (en) * 1999-01-15 2005-10-31 Altana Pharma Ag Phenanthridine-n-oxides with pde-iv inhibiting activity

Also Published As

Publication number Publication date
SI1147089T1 (sl) 2006-04-30
SK286946B6 (sk) 2009-08-06
PL205670B1 (pl) 2010-05-31
TR200501553T2 (tr) 2005-06-21
BR0007527B1 (pt) 2011-12-27
CA2359440A1 (en) 2000-07-20
EE05105B1 (et) 2008-12-15
WO2000042020A1 (en) 2000-07-20
BG65126B1 (bg) 2007-03-30
YU48701A (sh) 2004-05-12
EE200100350A (et) 2002-10-15
HRP20010578A2 (en) 2002-08-31
NO20013341D0 (no) 2001-07-05
IL144026A0 (en) 2002-04-21
CZ20012248A3 (cs) 2001-09-12
IL144026A (en) 2007-05-15
DE60024581D1 (de) 2006-01-12
BG105561A (en) 2001-12-29
CN1336919A (zh) 2002-02-20
NO20013341L (no) 2001-09-17
EA200100731A1 (ru) 2002-02-28
EP1147089A1 (en) 2001-10-24
KR100720906B1 (ko) 2007-05-25
CA2359440C (en) 2009-04-14
US6476025B1 (en) 2002-11-05
HK1040997B (en) 2006-07-14
AU2289600A (en) 2000-08-01
EP1650193A3 (en) 2006-10-04
PL348925A1 (en) 2002-06-17
KR20010086164A (ko) 2001-09-08
EA003780B1 (ru) 2003-08-28
NZ512872A (en) 2003-07-25
UA69436C2 (uk) 2004-09-15
ATE312081T1 (de) 2005-12-15
HU227624B1 (en) 2011-09-28
BR0007527A (pt) 2001-12-04
ID29070A (id) 2001-07-26
AU774868B2 (en) 2004-07-08
HUP0105001A3 (en) 2002-10-28
JP2002534508A (ja) 2002-10-15
HK1040997A1 (en) 2002-06-28
NO320182B1 (no) 2005-11-07
EP1650193A2 (en) 2006-04-26
EP1147089B1 (en) 2005-12-07
ES2254132T3 (es) 2006-06-16
CZ300366B6 (cs) 2009-05-06
SK9802001A3 (en) 2001-12-03
HUP0105001A2 (hu) 2002-04-29
TR200101938T2 (tr) 2001-12-21
DK1147089T3 (da) 2006-04-10
JP4653314B2 (ja) 2011-03-16
CN1152864C (zh) 2004-06-09
RS50297B (sr) 2009-09-08
ZA200104864B (en) 2003-04-15
DE60024581T2 (de) 2006-08-10

Similar Documents

Publication Publication Date Title
CY1106436T1 (el) Φαινυλοφαινανθριδινες με δραση αναστολης pde - ιv
ES2194180T3 (es) Nuevas fenantridinas.
MX9700557A (es) Dihidrobenzofuranos.
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
EE200000033A (et) Uudsed tetrasoolderivaadid
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
ATE269850T1 (de) 3-thiocarbamoylpyrazol-derivate als pestiziden
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
BR0108240A (pt) Desidroaminoácidos
ATE258930T1 (de) Dihydrobenzifurane
ATE294793T1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
ATE259813T1 (de) Triazolopyrimidinderivate
ATE374189T1 (de) Phthalazinon-derivate als pde 4 hemmer
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
ATE127803T1 (de) Mitomycinderivate.
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate
CY1110467T1 (el) 2-(ετερο-)αρυλιο υποκατεστημενα παραγωγα τετραϋδροκινολινης
ECSP993064A (es) Compuestos organicos
GR1001405B (el) Ενώσεις 2-πιπεραζινόνης και η παραγωγή και η χρησιμοποίηση αυτών.